pSivida is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. 
pSivida is focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon. The injectable, sustained release micro-insert ILUVIEN for the treatment of chronic Diabetic Macula Edema (DME), licensed to Alimera Sciences, Inc., and utilizes the third generation of the Durasert technology. pSivida's two FDA-approved products, Retisert and Vitrasert, are implants that provide long-term, sustained drug delivery to treat two other chronic diseases of the retina.


Company Growth (employees)
Type
Public
HQ
Watertown, US
Founded
1987
Size (employees)
20 (est)
pSivida was founded in 1987 and is headquartered in Watertown, US

pSivida Office Locations

pSivida has an office in Watertown
Watertown, US (HQ)
480 Pleasant St, Suite B300

pSivida Data and Metrics

pSivida Financial Metrics

pSivida's revenue was reported to be $590 k in Q3, 2017
USD

Revenue (Q3, 2017)

590 k

Net income (Q3, 2017)

(5.1 m)

EBIT (Q3, 2017)

(5.2 m)

Market capitalization (18-Aug-2017)

36.8 m

Cash (31-Mar-2017)

12.9 m
pSivida's current market capitalization is $36.8 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

3.5 m26.6 m1.6 m

Revenue growth, %

665%(94%)

R&D expense

9.6 m12.1 m14.4 m

General and administrative expense

7.5 m8.1 m9 m

Operating expense total

17 m20.1 m23.4 m

EBIT

(13.5 m)6.4 m(21.8 m)

EBIT margin, %

(388%)24%(1344%)

Interest income

72 k

Pre tax profit

(13.5 m)6.4 m(21.7 m)

Income tax expense

130 k(96 k)155 k

Net Income

(13.4 m)6.3 m(21.5 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

25.3 m521 k328 k466 m526 k324 k277 k6 m590 k

R&D expense

2.8 m2.8 m3.3 m3.5 b3.7 m3.1 m4.2 m3.2 m3.3 m

General and administrative expense

1.7 m1.9 m2 m2 b2 m2.3 m3.3 m2.9 m2.4 m

Operating expense total

4.5 m4.6 m5.4 m5.5 b5.8 m5.4 m7.5 m6.1 m5.8 m

EBIT

20.8 m(4.1 m)(5.1 m)(5 b)(5.2 m)(5.1 m)(7.2 m)(94 k)(5.2 m)

EBIT margin, %

82%(790%)(1540%)(1070%)(996%)(1573%)(2594%)(2%)(875%)

Interest income

3 k3 k6 k

Pre tax profit

20.8 m(4.1 m)(5 m)(5 b)(5.2 m)(5.1 m)(7.2 m)(67 k)(5.1 m)

Income tax expense

(226 k)38 k44 k41 m42 k34 k

Net Income

20.6 m(4.1 m)(5 m)(4.9 b)(5.2 m)(5 m)(7.2 m)(67 k)(5.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

15.3 m19.1 m15.3 m

Accounts Receivable

11.9 m

Inventories

547 k681 k483 k

Current Assets

19.3 m29.8 m30 m

PP&E

297 k338 k290 k

Total Assets

22.7 m32.4 m31.6 m

Accounts Payable

464 k744 k1.4 m

Current Liabilities

2.1 m3.3 m5.1 m

Total Liabilities

10.7 m

Additional Paid-in Capital

290.9 m293.1 m312.2 m

Retained Earnings

(277 m)(270.7 m)(292.2 m)

Total Equity

14.9 m23.4 m20.9 m

Financial Leverage

1.5 x1.4 x1.5 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

11.4 m29.8 m23 m14.1 m11.2 m24.9 m14.3 m11.7 m12.9 m

Current Assets

40.7 m37.3 m33.1 m25.2 m21.9 m34.3 m23.5 m18.5 m16.5 m

PP&E

261 k265 k280 k318 k311 k311 k257 k231 k241 k

Total Assets

43.7 m40.2 m35.7 m27.5 m24 m36.2 m24.9 m19.7 m17.5 m

Accounts Payable

1.1 m384 k812 k893 k303 k571 k1 m1.1 m741 k

Current Liabilities

2.3 m2.3 m2.2 m3 m3.9 m4 m4.8 m4.9 m4.9 m

Additional Paid-in Capital

291.2 m291.8 m292.4 m293.5 m294.3 m311.5 m313 m313.3 m316.2 m

Retained Earnings

(256.4 m)(260.5 m)(265.5 m)(275.6 m)(280.8 m)(285.8 m)(299.4 m)(299.4 m)(304.6 m)

Total Equity

35.8 m32.3 m27.8 m18.8 m14.4 m26.6 m14.4 m14.8 m12.5 m

Financial Leverage

1.2 x1.2 x1.3 x1.5 x1.7 x1.4 x1.7 x1.3 x1.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(13.4 m)6.3 m(21.5 m)

Depreciation and Amortization

139 k112 k152 k

Inventories

1.1 m(136 k)187 k

Accounts Payable

(213 k)292 k626 k

Cash From Operating Activities

8.4 m3.8 m(3.8 m)

Purchases of PP&E

(248 k)(161 k)(113 k)

Cash From Investing Activities

66 k(6.7 m)(4.5 m)

Cash From Financing Activities

19 m235 k17 m

Income Taxes Paid

263 k4 k
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

20.6 m(4.1 m)(5 m)(4.9 b)(5.2 m)(5 m)(7.2 m)(67 k)(5.1 m)

Accounts Payable

1.1 m384 k812 k893 k303 k571 k1 m1.1 m741 k
USDY, 2017

Revenue/Employee

29.5 k

Financial Leverage

1.4 x

pSivida Market Value History

Traffic Overview of pSivida

pSivida Online and Social Media Presence

pSivida News and Updates

BRIEF-pSivida reports positive results from investigator-sponsored phase 2 study of Medidur

* Results from investigator-sponsored phase 2 study of Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur in 2 years after implant Source text for Eikon: Further company coverage:

pSivida Company Life and Culture

You may also be interested in